The warning letter issued by the U.S. FDA was based on an inspection of Unit 11 of Aurobindo Pharma’s API facility at its Srikakulam plant in Andhra Pradesh in February. (Photographer: Prashanth Vishwanathan/Bloomberg)

Aurobindo Pharma Shares Slide After U.S. FDA Warning For Srikakulam Plant

Shares of Aurobindo Pharma Ltd. on Thursday fell to their lowest in nearly a year after the drugmaker received a warning letter from the U.S. Food and Drug Administration over manufacturing practic...

Bloomberg Quint

Add BloombergQuint App to Home screen.